DIAGENS

The company's core business revolves around developing and providing solutions that tackle key issues in human reproductive health, primarily through advanced diagnostics. DIAGENS operates in the medical diagnostics market, serving over 400 hospitals and medical institutions, including many top-tier hospitals and diagnostic centers in China. Its business model includes the sale of intelligent medical equipment, a Model-as-a-Service (MaaS) cloud platform, and providing localized self-training solutions for its clients. Since its angel round financing in late 2016, the company has successfully completed multiple funding rounds, including a Series C+ round, attracting significant investment from various capital firms.

DIAGENS has developed a portfolio of products built upon its proprietary universal medical imaging foundation model, iMedImage™. A key product is the AI AutoVision® Chromosome Karyotype Assisted Diagnosis System, which automates the entire process of chromosome analysis, from segmentation and counting to identifying abnormalities. This system significantly reduces the report turnaround time for chromosome analysis from about 30 days to 4-7 days. The company's product line also includes a complete automated workflow for cytogenetics, featuring the KayoFlow® series for automated cell harvesting and slide preparation, and the MetaSight® system for automated microscopic image scanning. In addition to its AI-driven diagnostic systems, DIAGENS produces consumables for assisted reproduction, such as ICSI micro-injection needles and holding pipettes, aiming to provide a domestic alternative to foreign-monopolized technologies.